These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 38617775)

  • 1. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study.
    Yan X; Zhao L; Wu F; Shen B; Zhou G; Feng J; Yue C; Zhu J; Yu S
    J Thorac Dis; 2024 Mar; 16(3):1787-1803. PubMed ID: 38617775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
    Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer.
    Xu M; Hao Y; Zeng X; Si J; Song Z
    J Thorac Dis; 2023 Apr; 15(4):1648-1657. PubMed ID: 37197488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study.
    Yang J; Zeng R; Zhou J; Luo L; Lyu M; Liu F; Sun X; Zhou L; Wang X; Bao Z; Chen W; Dumoulin DW; Gao B; Xiang Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1038-1050. PubMed ID: 35832441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study.
    Lin X; Deng H; Chu T; Chen L; Yang Y; Qiu G; Xie X; Qin Y; Liu M; Xie Z; Ouyang M; Li S; Song Y; Petrella F; Jakopovic M; Tsoukalas N; Solli P; Goto T; Saito Y; Zhou C
    Transl Lung Cancer Res; 2022 Nov; 11(11):2289-2305. PubMed ID: 36519018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study.
    Chen B; Wang J; Pu X; Li J; Wang Q; Liu L; Xu Y; Xu L; Kong Y; Li K; Xu F; Liang S; Cardona AF; Wu L
    Transl Lung Cancer Res; 2022 Oct; 11(10):2111-2124. PubMed ID: 36386462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse.
    Livanou ME; Nikolaidou V; Skouras V; Fiste O; Kotteas E
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer.
    Wang Y; Fu S; Zhang X; Du W; Luo L; Jiang Y; Zhou Y; Zhao Y; Yang Y; Zhao H; Fang W; Huang Y; Zhang L; Hong S
    Front Immunol; 2023; 14():1151385. PubMed ID: 37313402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
    Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
    Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
    JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and Advanced Non-Small-Cell Lung Cancer Patients with Chronic Infection.
    Zhao Z; Hu R; Chen Y; Zhou G; Yu S; Feng J
    Oncol Res Treat; 2022; 45(6):366-374. PubMed ID: 35231913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
    Torasawa M; Yoshida T; Takeyasu Y; Shimoda Y; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
    Cancer Med; 2023 Jun; 12(11):12388-12401. PubMed ID: 37062059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy.
    Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
    Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma.
    Jin Z; Cao Y; Lu Z; Liu C; Shen L
    Int Immunopharmacol; 2024 Aug; 137():112364. PubMed ID: 38865752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: A systematic review and meta-analysis.
    Feng Y; Tao Y; Chen H; Zhou Y; Tang L; Liu C; Hu X; Shi Y
    Thorac Cancer; 2023 Sep; 14(25):2536-2547. PubMed ID: 37551891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of immune checkpoint inhibitors plus recombinant human endostatin therapy as second-line treatment in advanced non-small-cell lung cancer with negative driver gene: a pilot study.
    Yang B; Li Y; Deng J; Yang H; Sun X
    Front Oncol; 2023; 13():1210267. PubMed ID: 38023216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer.
    Gao G; Jia K; Zhao S; Li X; Zhao C; Jiang T; Su C; Ren S; Zhou F; Zhou C
    Transl Lung Cancer Res; 2019 Dec; 8(6):920-928. PubMed ID: 32010570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
    Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
    J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.